2019 American Transplant Congress
Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR
*Purpose: Donor specific antibodies (DSA), whether pre-formed or developed de novo after kidney transplantation, have been associated with acute and chronic antibody mediated rejection, transplant…2019 American Transplant Congress
Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center
Pharmacy, NewYork-Presbyterian, New York, NY
*Purpose: Studies have demonstrated a mortality benefit with kidney transplantation (KT) in elderly patients, but there is little consensus over optimal immunosuppression. Older KT recipients…2019 American Transplant Congress
Expansion of Myeloid Derived Suppressor Cells Following Alum Administration
Massachusetts General Hospital, Boston, MA
*Purpose: Immunosuppressive medications, such as calcineurin inhibitors, are critical to the survival of the transplant allograft but come with significant morbidity to the recipient and…2019 American Transplant Congress
Performance Improvement Initiative: Ambulatory Tool to Improve Tacrolimus Intrapatient Variability (IPV) Monitoring in Kidney & Liver Transplant Recipients
1University of Cincinnati, Cincinnati, OH, 2UC Health, Cincinnati, OH
*Purpose: High tacrolimus (TAC) intrapatient variability (IPV) is associated with poorer outcomes. Manual monitoring of TAC IPV is labor intensive and not always feasible. As…2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…2019 American Transplant Congress
Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients
*Purpose: Comparison of two immunosuppressive protocols, steroid-free with antithymocyte globulin (ATG) induction, and steroid containing with basiliximab induction, regarding the incidence of PTDM, one year…2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy
*Purpose: Prior studies on the conversion of tacrolimus (Calcineurin Inhibitor; CNI) to belatacept have been limited in scope due to either the absence of, post-conversion…2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 138
- Next Page »